Silver Book Fact

Since 1980, 83 percent of gains in life expectancy for cancer patients have been attributable to new treatments.

Sun E, Lakdawall D, Ryes C, Goldman D, et al. The Determinants of Recent Gains in Cancer Survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database. J Clin Oncolo. 2008; 27(15S). http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.6616

Reference

Title
The Determinants of Recent Gains in Cancer Survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
Publication
J Clin Oncolo
Publication Date
2008
Authors
Sun E, Lakdawall D, Ryes C, Goldman D, et al
Volume & Issue
Volume 27, Issue 15S
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.  
  • Following the current path, the prostate cancer incidence rate will increase by 75.4% (786,000) between 2003 and 2023. If an alternative path is taken, there will be 21.5% (393,000) fewer…  
  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.